Filana Therapeutics
FLNA
137 hedge funds and large institutions have $41.1M invested in Filana Therapeutics in 2024 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 45 increasing their positions, 35 reducing their positions, and 54 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 35
6.98% more ownership
Funds ownership: 29.22% → 36.19% (+7%)
15% less funds holding
Funds holding: 161 → 137 (-24)
43% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 54
63% less call options, than puts
Call options by funds: $10.1M | Put options by funds: $27.2M
90% less capital invested
Capital invested by funds: $411M → $41.1M (-$370M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$14.8M |
| 2 |
Two Sigma Advisers
New York
|
+$10.7M |
| 3 |
Two Sigma Investments
New York
|
+$8.6M |
| 4 |
BlackRock
New York
|
+$8.37M |
| 5 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$7.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Tidal Investments
Milwaukee,
Wisconsin
|
-$11M |
| 2 |
GCM
Gallacher Capital Management
Lone Tree,
Colorado
|
-$7.5M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$5.11M |
| 4 |
Capital Fund Management (CFM)
Paris,
France
|
-$4.68M |
| 5 |
Morgan Stanley
New York
|
-$4.45M |
FLNA Hedge Fund Activity: Q4 2024 in Review
137 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q4 2024, worth a combined $41.1M — down 90% from $411M a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of FLNA and 31 opened new positions — a net loss of 23 holders — while 35 trimmed existing stakes and 45 added.
The largest buyer was UBS Group, adding an estimated $14.8M. The largest seller was Tidal Investments, exiting entirely with an estimated $11M sold.
- 137 institutional investors held Filana Therapeutics (FLNA) as of Q4 2024, down from 161 in Q3 2024.
- Funds reported $41.1M of Filana Therapeutics stock for Q4 2024, down 90% quarter-over-quarter.
- 31 funds opened new Filana Therapeutics positions in Q4 2024 and 54 closed out, a net change of -23 holders.
- The largest Filana Therapeutics buyer in Q4 2024 was UBS Group, an estimated $14.8M added.
- The largest Filana Therapeutics seller in Q4 2024 was Tidal Investments, an estimated $11M sold.
Based on aggregated 13F filings for Q4 2024.